← Go back

Date of filling in this questionnaire or last update: 21/12/2025
1. IDENTIFICATION & BASIC DESCRIPTION
Cohort name
  WeldCancer
Country
 

  • Sweden
Please provide any other information on the cohort location/s if needed
  Southern Sweden
Name
  Karin Broberg
Institution
  Karolinska Institutet/Lund University
Email
  karin.broberg@ki.se
Phone
  +46737823750
Personal website
  https://staff.ki.se/people/karbro
Website
 

  • https://ki.se/en/imm/project-exposure-to-welding-particles-and-lung-cancer-weldcancer
Name of committee
  Regional Ethics Committee Lund, Sweden
Upload files
 

Contact Principal Investigator (name)
  Karin Broberg
Data access policy (briefly describe)
  Other researchers can contact PI for access to data. The research aims should be in line with the ethical approval
Is this cohort part of a consortium? (name consortium)
  The European Occupational Exposome and Health Cohort Consortium
Participation in pooled analyses
 

  • The cohort is potentially interested in participating in pooled analyses of (European) occupational cohort studies (note pooled analyses also includes remote decentralized analyses that would not require any transfer of primary data as well as meta-analyses).
Main aim of cohort, please briefly describe the main objectives of the cohort
  To evaluate risk of cancer and cardiovascular disease among working welders.
Study design (please select as many as appropriate)
 

  • Prospective cohort
Source population (please select as many as appropriate)
 

  • Industry / occupation-based
Comparators (please select as many as appropriate)
 

  • External comparison of workers with other exposure
Inclusion criteria
  Nonsmokers at recruitment, male, 18-65 years
Exclusion criteria
  Current smokers, women
Enrollment
  Completed
Age range at entry (main cohort)
 

Minimum Maximum Mean
18 65 44

Men at enrollment
  228
Women at enrollment
  0
Children (<18 years) at enrollment
  0
Men at last follow-up
  174
Women at last follow-up
  0
Children (<18 years) at last follow-up
  0
2. OUTCOME FOLLOW-UP
Type of data for outcome follow-up (please select as many as appropriate)
 

  • Use of registers (specify)
  • Other (specify)
Specify: Other
 

  • Biomarkers of disease, blood pressure, endothelial function, etc
First follow-up period (provide year)
  2010
Last follow-up period (provide year)
  2026
Number of follow-ups after baseline (provide number)
  2
3. OCCUPATIONAL EXPOSURES
Source of exposure data collected (please select as many as appropriate)
 

  • Questionnaire, Personal (Self-reporting or interview)
  • Environmental samples
Occupational history/time frame
  Follow-up period
Occupational coding performed
  No
Types of exposure measurements
 

  • Biomarkers (see also section 5)
  • Personal external sampling
  • Workplace sampling
Methods for exposure assessment (please select as many as appropriate)
 

  • Expert assessment
  • Measurements (external sampling, biomarkers)
  • Self-report
Main categories
 

  • Dusts and fibres
  • Metals and metal oxides
Dusts and fibres | Inorganic dusts
 

  • Inorganic dusts, not specified
Metals and metal oxides
 

  • Other (specify)
Metals and metal oxides | Specify: Other
  Multielement analysis
Comments
  Respirable dust measured on filters. Metals in the filters analysed by multielement analysis (ICP-MS)
4. OUTCOMES EVALUATED
Baseline - type of outcome data collected (select more than one if applicable)
 

  • Biomarker (specify)
  • Clinical/functional evaluation, e.g. spirometry, ECGs (specify)
  • Questionnaire, individual (self-recording or interview)
Specify: Clinical/functional evaluation, e.g. spirometry, ECGs
  Blood pressure, endothelial function (Endopat)
Specify: Biomarker
  Genotoxicity, ox stress, proteins, epigenetic,
Follow-up - type of outcome data collected (select more than one if applicable)
 

  • Biomarker (specify)
  • Clinical/functional evaluation, e.g. spirometry, ECGs (specify)
  • Questionnaire, individual (self-recording or interview)
  • Registry-based
Specify: Clinical/functional evaluation, e.g. spirometry, ECGs
  Blood pressure, endothelial function
Specify: Biomarker
  Genotoxicity, oxidative stress, proteins, epigenetic
Outcome type (please select as many as appropriate)
 

  • Morbidity
Diagnostic groups based on ICD10
 

  • C + D Neoplasms
  • E Endocrinological disease
  • I Heart disease
  • I Cerebrovascular diseases
  • J Respiratory disease
C + D Neoplasms
 

  • Benign neoplasm
  • Carcinoma in situ
  • Leukemia
  • Malignant neoplasms gastro intes. system including liver, gall bladder, pancreas
  • Malignant neoplasm lung
  • Mesothelioma
  • Other malignant neoplasm of respiratory and intrathoracic organs, heart, pleura
  • Malignant neoplasm of bone and articular cartilage
  • Melanoma and other malignant neoplasms of skin
  • Neoplasms connective and soft tissue including nerves
  • Malignant neoplasm of breast
  • Malignant neoplasms, females gynecological
  • Malignant neoplasms of male genital organs
  • Malignant neoplasm of urinary tract and kidney
  • Malignant neoplasms of eye, brain and other parts of central nervous system
  • Malignant neoplasms of thyroid and other endocrine glands
  • Malignant neoplasms of ill-defined, secondary and unspecified sites
  • Malignant neoplasm without specification of site including excl. leukemia
  • Other, please state
E Endocrinological disease
 

  • Diabetes mellitus
I Heart disease
 

  • Rheumatic heart disease, unspecified
  • Hypertensive diseases
  • Angina pectoris
  • Acute myocardial infarction
  • Atrial septal defect
  • Chronic ischaemic heart disease
  • Pulmonary embolism
  • Other pulmonary heart diseases
  • Nonrheumatic mitral valve disorders
  • Pulmonary valve disorders
  • Endocarditis
  • Myocarditis
  • Cardiomyopathy
  • Atrioventricular arrhythmia
  • Heart failure
I Cerebrovascular diseases
 

  • Subarachnoid haemorrhage
  • Intracerebral haemorrhage
  • Cerebral infarction
  • Stroke, not specified as haemorrhage or infarction
  • Atherosclerosis
  • Aneurysm and dissection
  • Raynaud's syndrome
  • Thromboangiitis obliterans [Buerger]
  • Arterial embolism and thrombosis
  • Phlebitis and thrombophlebitis
  • Haemorrhoids
  • Oesophageal varices
  • Varicose veins of other sites
  • Lymphadenitis
  • Hypotension
J Respiratory disease
 

  • Acute upper respiratory infections of multiple and unspecified sites
  • Influenza
  • Viral pneumonia
  • Bacterial pneumonia
  • Pneumonia due to other infectious organisms, not elsewhere classified
  • Abscess of lung and mediastinum
  • Pyothorax
  • Acute bronchitis
  • Acute bronchiolitis
  • Vasomotor and allergic rhinitis
  • Chronic rhinitis, nasopharyngitis and pharyngitis
  • Chronic sinusitis
  • Nasal polyp
  • Chronic diseases of tonsils and adenoids
  • Diseases of vocal cords and larynx, not elsewhere classified
  • Chronic Bronchitis
  • Emphysema
  • Chronic obstructive pulmonary disease (COPD)
  • Asthma
  • Byssinosis
  • Bronchiectasis
  • Pneumoconiosis
  • Hypersensitivity pneumonitis due to organic dust
  • Other interstitial lung disease
  • Adult respiratory distress syndrome
  • Pulmonary edema
  • Pneumothorax
  • Respiratory failure, not elsewhere classified
5. BIOLOGICAL SAMPLES & ANALYSIS
Biological samples collected
 

  • Blood
  • Urine
  • Other
Specify: Other
  Mouth wash
Biological processing
 

  • DNA
  • RNA
Genetic and other lab analyses
 

  • Biomarkers (specify)
  • Epigenomics
  • Genomics / Other genetics (specify)
  • Proteomics
Specify: Biomarkers
  Oxidative stress markers, e.g. 8oxodG
Specify: Other genetics
  Telomere length, mitochondrial DNA copy number and methylation
6. Other Information
 

  • Alcohol
  • Anthropometry
  • Demographics
  • Education
  • Medical history
  • Physical exercise
  • Socioeconomic status
  • Smoking
Possibility for linkage to data registries/data enrichment via data linkage
 

  • Cancer incidence
  • Disease specific clinical database
  • Employment status
  • Hospital discharge
  • Medication usage
  • Mortality register
{6}